Advertisement
Screener

Bausch Health Companies Inc. (BHC) Payments for Derivative Instrument, Investing Activities

1.3 / 5 stars · 23/86 Roast Me

Bausch Health Companies Inc. Payments for Derivative Instrument, Investing Activities

Bausch Health Companies Inc. (BHC) reported Payments for Derivative Instrument, Investing Activities of $0 for the 12-month period ending 2016-12-31, per its 10-K filed 2017-03-01.

Discontinued › Cash Flow › Investing Activities

us-gaap:PaymentsForDerivativeInstrumentInvestingActivities · last filed 2017-03-01

  • Bausch Health Companies Inc. payments for derivative instrument, investing activities for the quarter ending 2016-12-31 was $0.00.
  • Bausch Health Companies Inc. payments for derivative instrument, investing activities for the quarter ending 2016-09-30 was $0.00.
  • Bausch Health Companies Inc. payments for derivative instrument, investing activities for the quarter ending 2015-12-31 was -$300.00K.
  • Bausch Health Companies Inc. payments for derivative instrument, investing activities for the quarter ending 2015-09-30 was $0.00.
  • Bausch Health Companies Inc. payments for derivative instrument, investing activities for fiscal 2016 was $0.00, a 100.00% decline from fiscal 2015.
  • Bausch Health Companies Inc. payments for derivative instrument, investing activities for fiscal 2015 was $26.00M.
  • Bausch Health Companies Inc. payments for derivative instrument, investing activities for fiscal 2014 was $0.00.
  • Bausch Health Companies Inc. payments for derivative instrument, investing activities for fiscal 2013 was $0.00.
Period endPayments for Derivative Instrument, Investing Activities 3 monthPayments for Derivative Instrument, Investing Activities 6 monthPayments for Derivative Instrument, Investing Activities 9 monthPayments for Derivative Instrument, Investing Activities 12 monthPayments for Derivative Instrument, Investing Activities 12 month as first filed
2016-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01
$0.00
derived: sum of 2 quarters · filed 2017-03-01
$0.00
10-K · filed 2017-03-01
2016-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09
$0.00
10-Q · filed 2016-11-09
2016-06-30$0.00
10-Q · filed 2016-08-09
2015-12-31-$300.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01
-$300.00K
derived: sum of 2 quarters · filed 2017-03-01
$26.00M
derived: sum of 3 quarters · filed 2017-03-01
$26.00M
10-K · filed 2017-03-01
$26.30M
10-K · filed 2016-04-29
2015-09-30$0.00
10-Q · filed 2015-10-26
$26.30M
derived: sum of 2 quarters · filed 2015-10-26
$26.30M
10-Q · filed 2016-11-09
2015-06-30$26.30M
10-Q · filed 2015-07-28
$26.30M
10-Q · filed 2016-08-09
2014-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01
$0.00
derived: sum of 2 quarters · filed 2017-03-01
$0.00
derived: sum of 3 quarters · filed 2017-03-01
$0.00
10-K · filed 2017-03-01
2014-09-30$0.00
10-Q · filed 2015-10-26
$0.00
derived: sum of 2 quarters · filed 2015-10-26
$0.00
10-Q · filed 2015-10-26
2014-06-30$0.00
10-Q · filed 2015-07-28
$0.00
10-Q · filed 2015-07-28
2013-12-31$0.00
10-K · filed 2016-04-29

Similar stocks

Stock NameCountryMarket CapPE Ratio
Braveheart Bio, Inc. (BRVE)United States$2.106B
PALVELLA THERAPEUTICS, INC. (PVLA)United States$2.105B-35.55
Trevi Therapeutics, Inc. (TRVI)United States$2.091B-51.93
OCULAR THERAPEUTIX, INC (OCUL)United States$2.159B-7.15
Prestige Consumer Healthcare Inc. (PBH)United States$2.163B13.03
Generate Biomedicines, Inc. (GENB)United States$2.052B
PERRIGO Co plc (PRGO)Ireland$2.038B-0.79
NEKTAR THERAPEUTICS (NKTR)United States$2.026B-9.05
Aurinia Pharmaceuticals Inc. (AUPH)$2.207B7.18
UroGen Pharma Ltd. (URGN)$2.015B-18.42